Text Size

Evaluation of Target Organs Damage in Hypertensive Patients (PreVENT-A GP)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01055353
First received: January 21, 2010
Last updated: May 11, 2011
Last verified: May 2011
History of Changes
  Purpose

Evaluation of target organs damage in hypertensive patients with no known cardiovascular (CV) or renal disease, stratified according to level of blood pressure control


Condition
Target Organs Damage
Hypertensive
no Known Cardiovascular
no Known Renal Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Evaluation of Target Organs Damage in Hypertensive Patients Followed in General Practice With no Known Cardiovascular (CV) or Renal Disease, Stratified According to Blood Pressure Control

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To evaluate the frequency of evaluation of preclinical target organs damage in hypertensive patients with no known cardiovascular or renal disease, by taking blood pressure (controlled or uncontrolled HT*) into account [ Time Frame: once / 1 Year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To describe the patient profile (socio-demographic, risk factors, comorbidities, global CV risk level estimated by the doctor and calculated retrospectively [according to ESH 2007]) associated with screening for target organs damage [ Designated as safety issue: No ]
  • To describe the modalities of patient follow-up and management [ Designated as safety issue: No ]
  • To compare the frequency of evaluation of target organs damage as a function of the modalities of management of CV risk factors at the time of the consultation. [ Designated as safety issue: No ]

Enrollment: 1857
Study Start Date: January 2010
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

First 2 consecutive adults with hypertension, with no known cardiovascular (CV) or renal disease, seen by general practitioner

Criteria

Inclusion Criteria:

  • diagnosis of essential hypertension (treated or untreated); HT not discovered on the day of the consultation; no documented clinical cardiovascular or renal disease.

Exclusion Criteria:

-

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01055353

  Show 908 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Study Director: Pascal Piedbois AstraZeneca
  More Information

No publications provided

Responsible Party: MC CD, AstraZeneca
ClinicalTrials.gov Identifier: NCT01055353     History of Changes
Other Study ID Numbers: NIS-CFR-DUM-2009/2
Study First Received: January 21, 2010
Last Updated: May 11, 2011
Health Authority: France: French Data Protection Authority

Keywords provided by AstraZeneca:
Target organs damage
hypertensive patients

Additional relevant MeSH terms:
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on May 19, 2013